Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Amoy to Develop Companion Diagnostics for AstraZeneca Drugs

publication date: Apr 18, 2022

Amoy Diagnostics, a Shanghai novel molecular diagnostics company, signed a collaboration agreement to develop companion diagnostics for AstraZeneca (LSE/NSDQ: AZN) drugs. The agreement covers development and commercialization. Initially, Amoy will focus on CDx products for genetic variations in patients with prostate or breast cancer. Earlier this month, Amoy announced a similar agreement with HutchMed for a NSCLC diagnostic. Founded in 2008, Amoy claims to be the largest provider of molecular diagnostics products for personalized healthcare in China, as well as a service center for oncology biomarker analysis. More details....

Stock Symbol: (SHZ: 300685)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital